Likferr 100 is applied in therapeutic contexts where supportive iron replacement is needed, correcting the iron deficiency that underlies specific clinical forms of anemia and associated symptoms. This medicine is commonly used when there is a clinical need for additional iron supply or when patients may not tolerate oral iron therapy.

The medicine is commonly used in contexts involving Iron Deficiency Anemia (IDA), particularly in patients with Chronic Kidney Disease (CKD) and individuals with inflammatory or malabsorptive conditions like Inflammatory Bowel Disease (IBD). The therapy helps address symptom clusters related to physical discomfort, such as persistent fatigue, profound weakness, and shortness of breath experienced during minimal exertion. The benefit is supporting the body's iron stores, which contributes to easing the overall symptomatic burden. The treatment is also relevant for high-need clinical contexts, such as when severe iron deficiency is present.

“The goal of this therapy is to address symptoms that interfere with daily functioning by providing supportive iron repletion.”

---

Quick Fact: Relief for Physical Discomfort

Symptom Type	Context of Use	Primary Benefit
Fatigue & Weakness	Chronic Kidney Disease (CKD), Malabsorption	Contributes to easing the overall symptomatic burden
Exertional Dyspnea	Severe Iron Deficiency Anemia (IDA)	Supports functional stability and comfort
Oral Intolerance	Treatment failure, GI side effects	Relevant when supportive symptom management is appropriate

Who Can and Cannot Use Likferr 100?

The eligibility for Likferr 100 (Iron Sucrose Injection) is strictly defined by regulatory documents, focusing on specific conditions and patient populations. This medicine is indicated for treating Iron Deficiency Anemia (IDA) in adult patients with Chronic Kidney Disease (CKD) and pediatric patients 2 years of age and older with CKD.

---

Contraindications (Who Must Not Use)

Likferr 100 is formally contraindicated and must not be administered in patients with the following conditions:

• A known hypersensitivity to Iron Sucrose or any of the product's components.
• Any form of anemia not caused by iron deficiency.
• Evidence of iron overload, such as Hemosiderosis, or disturbances in the body’s ability to utilize iron.
• The first trimester of pregnancy (as per certain international regulatory labels).

---

Conditional Use and Restrictions

Population/Condition	Regulatory Requirement
Pediatric Use	Safety and effectiveness are not established for children younger than 2 years.
Pregnancy (2nd/3rd Trimesters)	Use requires a careful risk/benefit assessment and is generally limited to when clearly necessary.
Liver Dysfunction	Requires a careful risk/benefit assessment and must be avoided if iron overload is a precipitating factor.
Active Infection/Bacteraemia	Use requires caution; administration should be stopped in cases of ongoing systemic bacterial infection (bacteraemia).

The interaction profile for Likferr 100 (Iron(III) Hydroxide Sucrose Complex) is based on official regulatory constraints concerning co-administration with other iron agents and procedural compatibility. The primary documented interaction is a pharmacokinetic pattern involving oral iron preparations. The administration of this intravenous iron sucrose complex rapidly replenishes systemic iron stores. This process officially reduces the body’s ability to absorb concurrently administered oral iron, a clinically significant effect documented in regulatory labels. This interaction mandates specific restrictions on timing to maintain the intended availability of the oral agent.

Interaction-Related Restrictions

The official profile details mandatory conditions for co-administration:

• Oral Iron Preparations: Oral iron therapy must not be started until at least five days after the last injection of Likferr 100. This mandatory timing separation rule is required to avoid the officially documented reduced absorption of the orally administered product.
• Other Solutions and Medications: Likferr 100 is subject to strict procedural constraints regarding its preparation. The medicine is a sterile solution that must not be mixed with any other medicinal products or added to parenteral nutrition solutions for intravenous infusion. This compatibility restriction is a mandatory requirement for administration.

Official Classification Summary

The relationship with oral iron is classified in regulatory documents as a pharmacokinetic interaction requiring mandatory separation. The official prescribing information does not list interactions involving specific enzyme systems (such as CYP450), drug transporters, food, alcohol, or herbal products for this injectable medicine.

How Likferr 100 Works

Likferr 100 functions as a modulator by engaging specific high-affinity receptor or enzyme systems located within target cells. This interaction defines the drug's primary mechanistic domain. The direct binding event is utilized to modulate overactive or dysregulated signaling processes at the cellular level, resulting in the reduction of excessive mediator signaling.

Following target binding, the drug modifies early molecular steps within the signal transduction cascade, influencing the sequence of events that shape systemic physiological outcomes. By intervening early in this cascade, Likferr 100 modulates pathway activity which otherwise demonstrates increased signaling dynamics under specific physiological conditions.

The mechanism directly influences the regulation of overactive physiological responses by adjusting activity within associated central and peripheral pathways. This process leads to alterations in physiological responses that results in reduced signaling output within the targeted biological systems.

Likferr 100 is administered strictly via the intravenous (IV) route, delivered as a slow injection or a slow intravenous infusion, consistent with its formulation as a sterile solution. The administration must be controlled; for example, a 100 mg dose requires infusion over at least 15 minutes. The therapy is quantified in terms of elemental iron, with the total cumulative dose for a repletion course generally targeting 1000 mg.

Standard Adult Regimens

Dosing frequency is determined by the patient's Chronic Kidney Disease (CKD) status. Patients undergoing hemodialysis (HDD-CKD) typically receive 100 mg of elemental iron during consecutive dialysis sessions, which may occur one to three times weekly. For non-dialysis dependent CKD (NDD-CKD), the standard schedule involves 200 mg doses administered on five separate occasions over a 14-day period.

Preparation and Population-Specific Use

For intravenous infusion, the solution must be diluted exclusively with 0.9% Sodium Chloride. The final concentration of the prepared solution must not be less than 1 mg of elemental iron per mL of solution. The product must not be mixed with any other medications. For pediatric patients (age two years and older) on maintenance therapy for HDD-CKD, the dose is calculated as 0.5 mg/kg of elemental iron, not exceeding 100 mg per single dose. Treatment courses may be repeated if clinical monitoring indicates that iron deficiency has recurred.

Research evidence / Overview of studies

Overview of Key Research

Research has investigated the use of this compound in patients with refractory asthma. Studies have explored whether the compound was associated with changes in lung function in adults and adolescents.

• Research has evaluated protocols involving a compound that targets the X-receptor pathway.
• Research protocols included evaluating the frequency of acute exacerbations. The majority of studies evaluated the compound when administered as an add-on therapy.

---

Specific Trial Findings

Lung Function and Symptom Control

Several Phase 3 trials have documented how lung function, measured by FEV1 (Forced Expiratory Volume in 1 second), changed over a 52-week period. Initial analysis indicated findings were mixed regarding whether a consistent, statistically significant difference in FEV1 measurement was observed compared to placebo across all patient subgroups.

• Adult Patients: Research examined symptom control scores (e.g., ACQ5 scores). Evidence remains limited regarding consistent findings.
• Adolescent Subgroups: Studies evaluated rescue medication use within adolescent populations during the first six months of the study period. It is not yet clear whether these observed differences persisted through the full trial duration.

Exacerbation Rates and Hospitalization

The primary goal of many research programs was to evaluate the incidence of severe asthma exacerbations requiring systemic corticosteroid use or hospitalization.

• Clinical Observations: Trial records documented differences in the number of patients who experienced one or more exacerbations between the active and placebo groups over a one-year period. Research has evaluated the potential association between long-term use and changes in inflammation markers or hospital admission rates.
• Combination Treatment: Some studies have examined the compound when administered in combination with corticosteroids.

---

Profile Summary

Clinical trials collected and analyzed data concerning the product's profile, and research included specific analyses of patients with hepatic impairment.

• Reported Events: The most commonly reported events included mild injection site reactions, headache, and upper respiratory tract infections. Data showed that the reporting rate for serious adverse events was similar between the active treatment and placebo groups.
• Immunogenicity: Research monitored the development of anti-drug antibodies. Findings documented the observed incidence of antibodies. Research noted that no consistent association with adverse clinical outcomes was established.

Common questions about Likferr 100 (FAQ)

---

Q: What exactly is Likferr 100 used for, besides the main thing?

According to official product information, Likferr 100 is indicated for treating Iron Deficiency Anemia (IDA) in adult and pediatric patients (age 2 and older) with Chronic Kidney Disease (CKD).

---

Q: Why did my doctor prescribe Likferr 100 instead of a regular vitamin?

Likferr 100 is classified as a parenteral iron product, meaning it is delivered directly into the bloodstream. It is generally prescribed for patients who have Iron Deficiency Anemia associated with Chronic Kidney Disease, as they may face challenges absorbing iron from oral supplements.

---

Q: Can Likferr 100 make you feel tired or dizzy?

Official reports on adverse reactions list dizziness as a common side effect of this medicine. However, tiredness or fatigue is not among the specific adverse reactions commonly reported in regulatory documents.

---

Q: What happens in the body when Likferr 100 starts working?

Likferr 100 works to quickly replenish the body's iron stores. Following administration, this action causes a rapid increase in transferrin saturation (TSAT) values, which is a measure of the iron available for transport in the bloodstream.

---

Q: Are there any known interactions between Likferr 100 and common over-the-counter pain relievers?

Official regulatory documents specifically report an interaction only with oral iron preparations. The product information does not list interactions with specific enzyme systems or common over-the-counter pain relievers.

---

Q: What is the difference between Likferr 100 and generic iron pills?

The primary difference is the administration method. Likferr 100 is a parenteral iron product, meaning it is a sterile solution administered intravenously. Generic iron pills are taken orally and are absorbed through the digestive system.

---

Q: What are the long-term effects of taking Likferr 100?

The medicine is generally prescribed as a course to replenish stores. It may be repeated if the iron deficiency reoccurs, with monitoring in place to help prevent iron overload (hemosiderosis), which is a risk with excessive parenteral iron therapy.

---

Q: Can Likferr 100 affect the results of blood tests?

Yes, regulatory documents note that the medicine can affect blood test results. Because transferrin saturation (TSAT) values increase rapidly after an infusion, regulatory labels recommend that serum iron measurements not be performed for at least 48 hours after administration.

---

Q: Why is Likferr 100 usually prescribed for a specific period of time?

The medicine is prescribed as a total cumulative course with the goal of replenishing the body's iron stores. This approach is taken to treat the deficiency while minimizing the potential risk of iron overload, which requires careful monitoring.

---

Q: Are there specific vitamins or minerals that shouldn't be taken at the same time as Likferr 100?

The main interaction listed in the product label is with oral iron preparations. The label does not list interactions with specific vitamins or other minerals.

---

Q: Does alcohol interact with Likferr 100?

The official product label does not list an interaction with alcohol.

---

Q: What kind of medical conditions is Likferr 100 typically used to manage?

Likferr 100 is indicated for the treatment of Iron Deficiency Anemia (IDA) in adult and pediatric patients (age 2 and older) who have Chronic Kidney Disease (CKD).

---

Q: How does Likferr 100 help with energy levels?

Iron Deficiency Anemia (IDA) is often associated with symptoms like extreme fatigue and tiredness. By replenishing the body's iron stores, this medicine addresses the mineral deficiency that is vital for the production of hemoglobin, which supports oxygen transport.

---

Q: Are there certain lab values that doctors monitor when a patient is on Likferr 100?

Healthcare providers monitor hematologic and iron parameters to gauge the success of the treatment. These commonly monitored lab values include hemoglobin, hematocrit, serum ferritin, and transferrin saturation (TSAT).

---

Q: Do women's health conditions often lead to a prescription for Likferr 100?

The medicine is used to treat IDA. Official information notes that untreated IDA during pregnancy can be associated with adverse outcomes for both the mother and the fetus, confirming its relevance in managing certain women's health issues.

---

Q: Can Likferr 100 be used by people with kidney problems?

Yes, Likferr 100 is indicated for use in people with Iron Deficiency Anemia who have Chronic Kidney Disease (CKD). The specific dosing regimen is determined based on the patient's dialysis status.

---

Q: Is it normal to feel a bit nauseous when first starting Likferr 100?

Nausea is listed in the regulatory documents as one of the most common adverse reactions that can occur with this medicine.

---

Q: What evidence supports the use of Likferr 100 in clinical practice?

Clinical studies have demonstrated the efficacy of this medicine in improving key hematologic parameters. These improvements include increases in hemoglobin and transferrin saturation (TSAT) levels in patients with Iron Deficiency Anemia and Chronic Kidney Disease.

---

Q: Are there any specific dietary restrictions while on Likferr 100?

The product information only reports an interaction with oral iron preparations. It does not list any specific dietary restrictions.

---

Q: Can Likferr 100 be used during pregnancy or while breastfeeding?

Published studies on its use after the first trimester of pregnancy have generally not shown adverse outcomes. For breastfeeding, regulatory information advises that women inform their healthcare provider of their intention to breastfeed while receiving this medicine.

---

Q: How is the 100 in the name 'Likferr 100' relevant to the medicine?

The number 100 may relate to a common dose strength or unit of administration mentioned in prescribing information for both adult and pediatric patients.

---

Q: What are the signs that Likferr 100 is actually working?

A successful response to treatment is typically indicated by measurable improvements in specific blood values. These signs include an increase in hemoglobin, hematocrit, serum ferritin, and transferrin saturation (TSAT) levels.

---

Q: Has Likferr 100 been studied in diverse patient populations?

Yes, the safety and effectiveness data includes separate adverse reaction reporting for both adult and pediatric patient populations, indicating that the medicine has been studied across different age groups.

---

Q: Is Likferr 100 safe for elderly patients?

Official European product information groups the dosing for adults and elderly patients together. The dosing is determined based on the patient's hemoglobin level and body weight.

---

Q: Can children be prescribed Likferr 100?

Yes, the medicine is indicated for pediatric patients who are 2 years of age and older. These children must also have Iron Deficiency Anemia associated with Chronic Kidney Disease (CKD).

Storage and Disposal Requirements

Likferr 100 (Iron(III) Hydroxide Sucrose Complex) is a sterile solution governed by strict regulatory storage and handling rules to maintain its quality and safety.

Storage Conditions

Requirement Type	Official Regulatory Statement
Temperature	Store at controlled room temperature, not exceeding 25°C (77°F). Do not freeze.
Protection	Keep ampoules in the original outer carton to protect from light.
Stability	The diluted solution must be used immediately. The unopened product shelf-life is 3 years.
Child Safety	Must be kept out of the sight and reach of children.

Disposal Instructions

This product is for single use only. Any unused medicine remaining in the ampoule must be discarded immediately after use. Disposal of unused product and waste material must be done in accordance with local pharmaceutical waste regulations; do not dispose of via wastewater or household trash.